Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,020 | 167 | 837 |
| Samples | 533 | 120 | 407 |
| Peptides | 401 | 90 | 318 |
Function
GRIN2C · Glutamate ionotropic receptor NMDA type subunit 2C
This gene encodes a subunit of the N-methyl-D-aspartate (NMDA) receptor, which is a subtype of ionotropic glutamate receptor. NMDA receptors are found in the central nervous system, are permeable to cations and have an important role in physiological processes such as learning, memory, and synaptic development. The receptor is a tetramer of different subunits (typically heterodimer of subunit 1 with one or more of subunits 2A-D), forming a channel that is permeable to calcium, potassium, and sodium, and whose properties are determined by subunit composition. Alterations in the subunit composition of the receptor are associated with pathophysiological conditions such as Parkinson's disease, Alzheimer's disease, depression, and schizophrenia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2013].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 395 amino-acid changes on canonical ENST00000293190 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRIN2C · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRIN2C – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Endometrial Carcinoma | 6/42 14% | 14/612 2% |
| Melanoma | 10/210 5% | 47/1899 2% |
| Colorectal Carcinoma | 16/143 11% | 75/3239 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Gastric Carcinoma | 6/74 8% | 32/1809 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Burkitts Lymphoma | 4/32 12% | 0/196 0% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 14/1390 1% |
| Other Solid Cancers | 2/94 2% | 21/1515 1% |
| Thyroid Gland Carcinoma | 4/45 9% | 18/1592 1% |
| Cervical Carcinoma | 1/35 3% | 5/422 1% |
| Bladder Carcinoma | 1/58 2% | 12/956 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 28/2550 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Other Sarcomas | 1/69 1% | 7/699 1% |
| Hepatocellular Carcinoma | 5/46 11% | 17/2210 1% |
| Non-Cancerous | 1/104 1% | 8/830 1% |
| Head and Neck Carcinoma | 2/85 2% | 13/1574 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Neuroendocrine Tumour | 5/154 3% | 1/577 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 5/810 1% |
| Biliary Tract Carcinoma | 2/54 4% | 6/950 1% |
| Small Cell Lung Carcinoma | 3/9 33% | 3/752 0% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Glioma | 2/52 4% | 13/2127 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
Mutation Distribution
Where GRIN2C is mutated · all tissues, split by cell line vs tissue
How many mutations in GRIN2C were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,020 mutations in GRIN2C
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|